Domaines d’application et enjeux de l’ingénierie et de la thérapie cellulaires et tissulaires: Quel choix stratégique pour l’EFS ?

A new medical field, known as regeneration medicine is developing and attracting more and more researchers and practitioners. Whereas hematopoietic cell-based therapies have already proven their efficacy in numerous – malignant or not – diseases, non-hematopoietic cell-based therapies have not. They can be useful to dozens, if not hundreds, of patients with various disorders, such as cardiopathy, diabetes, some types of cancer, osteoarticular and neurodegenerative disorders. In these fields, numerous clinical applications are possible for mesenchymal stem cells. Cell and tissue (corneas, bone, skin) therapy products require the definition of pharmaceutical standards with new European requirements in terms of quality and safety. The legitimacy of the Établissement Français du Sang (EFS) in cell and tissue engineering activities is established, it is recognized by most specialists and by regulatory authorities and has been asserted by the orientations of its “contrat d’objectifs et de moyens”. An independent committee has been set up by the EFS President to define an EFS-specific strategy. This committee made up of qualified specialists was required to draw up a rational organization plan for these activities, in order for EFS to be in a position to produce cells and tissues according to pharmaceutical standards. The committee proposals are based on economic data and an inventory of existing cell and tissue engineering activities. Public/private partnerships are required and efforts must focus towards the industrial valorization of EFS expertise in R&;D activities and staff know-how. Implementing such a new organization requires national management and the cooperation of institutional actors (university hospitals, cancer treatment centers, universities). For the success of this approach, EFS personnel must be convinced of its legitimacy and new skills must be encouraged. With its numerous assets, EFS can be ambitious and assert itself as a major actor in cell and tissue engineering in Europe.